Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept

Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with...

Full description

Saved in:
Bibliographic Details
Published in:Immune network 2022-10, Vol.22 (5), p.1-16
Main Authors: Oh, Sangwook, Payne, Aimee S
Format: Article
Language:English
Subjects:
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c420t-c44c4a4a7cc5fae33b6fb10cd02d343ac881cd9ab77750c6dc8a8867506b3e043
cites cdi_FETCH-LOGICAL-c420t-c44c4a4a7cc5fae33b6fb10cd02d343ac881cd9ab77750c6dc8a8867506b3e043
container_end_page 16
container_issue 5
container_start_page 1
container_title Immune network
container_volume 22
creator Oh, Sangwook
Payne, Aimee S
description Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with monoclonal Abs targeting B cell lineage markers is standard care therapy for several B cell-mediated autoimmune disorders. In the last 5 years, genetically-engineered cellular immunotherapies targeting B cells have shown superior efficacy and long-term remission of B cell malignancies compared to historical clinical outcomes using B cell depletion with monoclonal Ab therapies. This has raised interest in understanding whether similar durable remission could be achieved with use of genetically-engineered cell therapies for autoimmunity. This review will focus on current human clinical trials using engineered cell therapies for B cell-associated autoimmune diseases.
doi_str_mv 10.4110/in.2022.22.e37
format article
fullrecord <record><control><sourceid>nurimedia_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9634148</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><nurid>NODE11157588</nurid><sourcerecordid>NODE11157588</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-c44c4a4a7cc5fae33b6fb10cd02d343ac881cd9ab77750c6dc8a8867506b3e043</originalsourceid><addsrcrecordid>eNpVkc1r3DAQxUVpaTZprj0WXQq97FZfluQcCsHZfEBockjOQpbHGwVb2kp2If99tGyytPCQBuanN4MeQl8pWQlKyU8fVowwtioCrj6gBSM1W0qpq49oQataL5lk9RE6zvmZECm4qj6jIy65prWkC2TXYeMDQPJhgxsYBvzwBMluPWTcx4TP5yn6cZwD4AufwWbIZ_gyxRHfJ3CDD97ZAU8RN-_1fYqxx0VNDA620xf0qbdDhtO3-wQ9Xq4fmuvl7d3VTXN-u3SCkamcwgkrrHKu6i1w3sq-pcR1hHVccOu0pq6rbauUqoiTndNWa1lq2XIggp-gX3vf7dyO0DkIU7KD2SY_2vRiovXm_07wT2YT_5packGFLgY_3gxS_DNDnszosytfYgPEORumuKI7cIeu9qhLMecE_WEMJWaXi_HB7HIxRSWX8uDbv8sd8PcgCvB9D4S5tKDz9sD8vrtYU0orVWnNXwHxppd-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2737114838</pqid></control><display><type>article</type><title>Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept</title><source>PubMed Central Free</source><creator>Oh, Sangwook ; Payne, Aimee S</creator><creatorcontrib>Oh, Sangwook ; Payne, Aimee S</creatorcontrib><description>Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with monoclonal Abs targeting B cell lineage markers is standard care therapy for several B cell-mediated autoimmune disorders. In the last 5 years, genetically-engineered cellular immunotherapies targeting B cells have shown superior efficacy and long-term remission of B cell malignancies compared to historical clinical outcomes using B cell depletion with monoclonal Ab therapies. This has raised interest in understanding whether similar durable remission could be achieved with use of genetically-engineered cell therapies for autoimmunity. This review will focus on current human clinical trials using engineered cell therapies for B cell-associated autoimmune diseases.</description><identifier>ISSN: 1598-2629</identifier><identifier>EISSN: 2092-6685</identifier><identifier>DOI: 10.4110/in.2022.22.e37</identifier><identifier>PMID: 36381961</identifier><language>eng</language><publisher>Korea (South): 대한면역학회</publisher><subject>Review</subject><ispartof>Immune network, 2022-10, Vol.22 (5), p.1-16</ispartof><rights>Copyright © 2022. The Korean Association of Immunologists.</rights><rights>Copyright © 2022. The Korean Association of Immunologists 2022 The Korean Association of Immunologists</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-c44c4a4a7cc5fae33b6fb10cd02d343ac881cd9ab77750c6dc8a8867506b3e043</citedby><cites>FETCH-LOGICAL-c420t-c44c4a4a7cc5fae33b6fb10cd02d343ac881cd9ab77750c6dc8a8867506b3e043</cites><orcidid>0000-0001-9389-7918 ; 0000-0003-0092-9031</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634148/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634148/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36381961$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oh, Sangwook</creatorcontrib><creatorcontrib>Payne, Aimee S</creatorcontrib><title>Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept</title><title>Immune network</title><addtitle>Immune Netw</addtitle><description>Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with monoclonal Abs targeting B cell lineage markers is standard care therapy for several B cell-mediated autoimmune disorders. In the last 5 years, genetically-engineered cellular immunotherapies targeting B cells have shown superior efficacy and long-term remission of B cell malignancies compared to historical clinical outcomes using B cell depletion with monoclonal Ab therapies. This has raised interest in understanding whether similar durable remission could be achieved with use of genetically-engineered cell therapies for autoimmunity. This review will focus on current human clinical trials using engineered cell therapies for B cell-associated autoimmune diseases.</description><subject>Review</subject><issn>1598-2629</issn><issn>2092-6685</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkc1r3DAQxUVpaTZprj0WXQq97FZfluQcCsHZfEBockjOQpbHGwVb2kp2If99tGyytPCQBuanN4MeQl8pWQlKyU8fVowwtioCrj6gBSM1W0qpq49oQataL5lk9RE6zvmZECm4qj6jIy65prWkC2TXYeMDQPJhgxsYBvzwBMluPWTcx4TP5yn6cZwD4AufwWbIZ_gyxRHfJ3CDD97ZAU8RN-_1fYqxx0VNDA620xf0qbdDhtO3-wQ9Xq4fmuvl7d3VTXN-u3SCkamcwgkrrHKu6i1w3sq-pcR1hHVccOu0pq6rbauUqoiTndNWa1lq2XIggp-gX3vf7dyO0DkIU7KD2SY_2vRiovXm_07wT2YT_5packGFLgY_3gxS_DNDnszosytfYgPEORumuKI7cIeu9qhLMecE_WEMJWaXi_HB7HIxRSWX8uDbv8sd8PcgCvB9D4S5tKDz9sD8vrtYU0orVWnNXwHxppd-</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Oh, Sangwook</creator><creator>Payne, Aimee S</creator><general>대한면역학회</general><general>The Korean Association of Immunologists</general><scope>DBRKI</scope><scope>TDB</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9389-7918</orcidid><orcidid>https://orcid.org/0000-0003-0092-9031</orcidid></search><sort><creationdate>20221001</creationdate><title>Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept</title><author>Oh, Sangwook ; Payne, Aimee S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-c44c4a4a7cc5fae33b6fb10cd02d343ac881cd9ab77750c6dc8a8867506b3e043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oh, Sangwook</creatorcontrib><creatorcontrib>Payne, Aimee S</creatorcontrib><collection>DBPIA - 디비피아</collection><collection>DBpia - NuriMedia Korean Studies Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immune network</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oh, Sangwook</au><au>Payne, Aimee S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept</atitle><jtitle>Immune network</jtitle><addtitle>Immune Netw</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>22</volume><issue>5</issue><spage>1</spage><epage>16</epage><pages>1-16</pages><issn>1598-2629</issn><eissn>2092-6685</eissn><abstract>Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with monoclonal Abs targeting B cell lineage markers is standard care therapy for several B cell-mediated autoimmune disorders. In the last 5 years, genetically-engineered cellular immunotherapies targeting B cells have shown superior efficacy and long-term remission of B cell malignancies compared to historical clinical outcomes using B cell depletion with monoclonal Ab therapies. This has raised interest in understanding whether similar durable remission could be achieved with use of genetically-engineered cell therapies for autoimmunity. This review will focus on current human clinical trials using engineered cell therapies for B cell-associated autoimmune diseases.</abstract><cop>Korea (South)</cop><pub>대한면역학회</pub><pmid>36381961</pmid><doi>10.4110/in.2022.22.e37</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0001-9389-7918</orcidid><orcidid>https://orcid.org/0000-0003-0092-9031</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1598-2629
ispartof Immune network, 2022-10, Vol.22 (5), p.1-16
issn 1598-2629
2092-6685
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9634148
source PubMed Central Free
subjects Review
title Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A12%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-nurimedia_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Engineering%20Cell%20Therapies%20for%20Autoimmune%20Diseases:%20From%20Preclinical%20to%20Clinical%20Proof%20of%20Concept&rft.jtitle=Immune%20network&rft.au=Oh,%20Sangwook&rft.date=2022-10-01&rft.volume=22&rft.issue=5&rft.spage=1&rft.epage=16&rft.pages=1-16&rft.issn=1598-2629&rft.eissn=2092-6685&rft_id=info:doi/10.4110/in.2022.22.e37&rft_dat=%3Cnurimedia_pubme%3ENODE11157588%3C/nurimedia_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c420t-c44c4a4a7cc5fae33b6fb10cd02d343ac881cd9ab77750c6dc8a8867506b3e043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2737114838&rft_id=info:pmid/36381961&rft_nurid=NODE11157588&rfr_iscdi=true